Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Roche describes new inhibitors of MDM2/p53 interaction with utility in cancer

July 16, 2003

Low response rate for SU-5416 in refractory myeloproliferative disorders

July 16, 2003

FDA clears phase I study of PHP as an adjunct to IL-2 cancer therapy

July 15, 2003

Encouraging results from ongoing phase I/II trial with MetXia in breast cancer

July 15, 2003

Synthetic Hsp90 ATPase inhibitor identified as potential new lead anticancer agent

July 15, 2003

VEGF receptor tyrosine kinase inhibitor E-7080, a promising agent for solid tumors

July 15, 2003

Efaproxiral reported to improve survival in cancer patients with brain metastases

July 15, 2003

Further preclinical characterization of AG-013736, a VEGFR/PDGFR TK inhibitor

July 15, 2003

Orally available Src tyrosine kinase inhibitor characterized in vitro and in vivo

July 15, 2003

Roche presents new series of antitumor agents targeting CDK2

July 15, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...